HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

Benzinga · 3d ago
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.